Sotrastaurin
- Generic Name
- Sotrastaurin
- Drug Type
- Small Molecule
- Chemical Formula
- C25H22N6O2
- CAS Number
- 425637-18-9
- Unique Ingredient Identifier
- 7I279E1NZ8
- Background
Sotrastaurin has been used in trials studying the basic science and treatment of Uveal Melanoma, Richter Syndrome, Prolymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, and Recurrent Small Lymphocytic Lymphoma, among others.
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation
- Conditions
- Prolymphocytic LeukemiaRecurrent Mantle Cell LymphomaRefractory Chronic Lymphocytic LeukemiaRichter SyndromeRecurrent Small Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- James Blachly
- Registration Number
- NCT02285244
Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 30
- Registration Number
- NCT02273219
- Locations
- ๐บ๐ธ
Columbia University Medical Center, New York, New York, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธBascom Palmer Eye Institute of University Of Miami Medical Center, Miami, Florida, United States
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
- Conditions
- CD79 Mutant or ABC-subtype Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT01854606
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center Onc. Dept., New York, New York, United States
๐บ๐ธWashington University School of Medicine Dept of Oncology., Saint Louis, Missouri, United States
๐บ๐ธSarah Cannon Research Institute Dept of Onc, Nashville, Tennessee, United States
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
- First Posted Date
- 2013-02-28
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 38
- Registration Number
- NCT01801358
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center Dept of Onc.., New York, New York, United States
๐ฌ๐งPfizer Investigative Site, London, United Kingdom
๐บ๐ธDana Farber Cancer Institute Dept. Onc, Boston, Massachusetts, United States
CAEB071 Thorough QTc Study in Healthy Volunteers
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2012-05-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT01594255
- Locations
- ๐บ๐ธ
Novartis Investigational Site, Austin, Texas, United States
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 153
- Registration Number
- NCT01430416
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering MSKCC 4, New York, New York, United States
๐ฌ๐งNovartis Investigative Site, London, United Kingdom
๐บ๐ธDana Farber Cancer Institute DFCI - Brookline, Boston, Massachusetts, United States
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2011-07-26
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT01402440
- Locations
- ๐บ๐ธ
City of Hope National Medical Center, Duarte, California, United States
๐ฌ๐งNovartis Investigative Site, Manchester, United Kingdom
๐บ๐ธOhio State Comprehensive Cancer Center/James Cancer Hospital Ohio State, Columbus, Ohio, United States
Efficacy, Safety, Tolerability, Pharmacokinetics of Sotrastaurin-tacrolimus vs. Mycophenolic Acid-tacrolimus in de Novo Liver Transplant Patients
- Conditions
- Liver Transplantation
- Interventions
- Drug: MMF(1000mg bid) + tacrolimus + standard of care medications
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT01128335
- Locations
- ๐จ๐ญ
Novartis Investigative Site, Zurich, Switzerland
Efficacy, Safety, Tolerability, and Pharmacokinetics of Sotrastaurin Combined With Tacrolimus vs. a Mycophenolic Acid-tacrolimus Regimen in Renal Transplant Patients
- Conditions
- Renal Transplantation
- Interventions
- Drug: mycophenolic acid + tacrolimus + standard of care medications
- First Posted Date
- 2010-02-08
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 298
- Registration Number
- NCT01064791
- Locations
- ๐ฌ๐ง
Novartis Investigative Site, Manchester, United Kingdom
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
- Conditions
- Moderate and Severe Plaque Psoriasis
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 336
- Registration Number
- NCT00885196
- Locations
- ๐บ๐ธ
Kansas City Dermatology, PA, Overland Park, Kansas, United States
๐บ๐ธPalmetto Clinical Trial Services, Greenville, South Carolina, United States
๐น๐ทNovartis Investigative Site, Manisa, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.